Moreover, the treatment of human lung cancer cells with ovalitenone at non-toxic concentrations significantly decreased the levels of N-cadherin, snail, and slug, while it increased E-cadherin (Figure 4a,b), indicating the effect of this compound in terms of its inhibition of EMT; thereby, resulting in the inhibition of cell movement from the suppression of the AKT/mTOR pathways (Figure 4c,d). Here, CDH2 is linked to lung cancer.